Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
百时美施贵宝(US:BMY) Businesswire·2025-10-25 23:00PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACR25--BMS Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-Tâ"¢ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR. ...